Understanding how certain drugs affect multiple myeloma based on genetic differences.
Official title: Revealing the cis-Regulatory Function of IMiDs in Multiple Myeloma”.
Funded at Emory University · NIH-10980423 · Data updated 2026-11-12
This study is looking at how certain genes might affect how well multiple myeloma patients respond to specific treatments, and it invites patients to share genetic samples to help understand why some people benefit from these drugs while others do not.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | December 7, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $187,448 |
| NIH project number | 5K22CA266739-03 |
| Project ID | NIH-10980423 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multiple myeloma, particularly those with specific genetic alterations.
✕Less likely to help
Patients with non-multiple myeloma conditions or those who do not have identifiable genetic alterations related to the study may not benefit.
What this research studies
This research investigates the role of specific genetic factors in how multiple myeloma patients respond to immunomodulatory imide drugs (IMiDs). By analyzing the binding of transcription factors to genomic regions, the study aims to identify why some patients benefit from these treatments while others do not. The approach involves examining the unique molecular subtypes of myeloma and how they interact with these drugs. Patients may be involved in providing genetic samples to help clarify these relationships.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for multiple myeloma, improving outcomes for patients.
How similar studies have gone: Previous research has shown promising results in understanding the genetic basis of drug responses in various cancers, indicating potential for success in this area as well.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Barwick, Benjamin Gabriel — Emory University
- Study coordinator: Barwick, Benjamin Gabriel
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.